HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Immuneering Corporation

Contributing Author

Recent Articles by Immuneering Corporation

Jan-07
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP IMRX GlobeNewswire
Dec-23
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 IMRX GlobeNewswire
Dec-17
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA IMRX GlobeNewswire
Dec-16
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) IMRX GlobeNewswire
Nov-25
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference IMRX GlobeNewswire
Nov-12
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates IMRX GlobeNewswire
Nov-04
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 IMRX GlobeNewswire
Sep-26
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 IMRX GlobeNewswire
Sep-25
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi IMRX GlobeNewswire
Sep-24
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi IMRX GlobeNewswire
Sep-24
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP IMRX GlobeNewswire
Sep-16
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board IMRX GlobeNewswire
Sep-10
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 IMRX GlobeNewswire
Aug-26
Immuneering Announces Closing of $25 Million Private Placement IMRX GlobeNewswire
Aug-25
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib IMRX GlobeNewswire
Aug-21
Immuneering Announces $25 Million Private Placement IMRX GlobeNewswire
Aug-13
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire
Jul-09
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib IMRX GlobeNewswire
Jun-17
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients IMRX GlobeNewswire
Jun-16
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 IMRX GlobeNewswire
May-29
Immuneering to Present at the Jefferies Global Healthcare Conference IMRX GlobeNewswire
May-05
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates IMRX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.